

Rabbit Anti-TOM34 Polyclonal: RC0419-0.1ML

Intended Use: For Research Use Only

Description: TOM34 (translocase of outer mitochondrial membrane 34), also known as TOMM34, URCC3 or HTOM34P, is a ubiquitously expressed 309 amino acid protein that contains six TPR repeats. Localized to the cytoplasmic side of the mitochondrion, TOM34 is involved in the import of precursor proteins into mitochondria. The encoded protein has a chaperone-like activity, binding the mature portion of unfolded proteins and aiding their import into mitochondria. This protein, which is found in the cytoplasm and sometimes associated with the outer mitochondrial membrane, has a weak ATPase activity and contains 6 TPR repeats. Expression of TOM34 is upregulated in colon cancer cells and is thought to be involved in tumor progression. TOM34 may, therefore, be a novel target for therapeutic anti-cancer drugs.

Specifications:


Clone: Polyclonal
 Source: Rabbit
 Isotype: IgG
 Reactivity: Human, mouse
 Immunogen: Recombinant full length protein of human TOM34
 Localization: Cytoplasm, mitochondrion outer membrane
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, WB
 Package:

Description	Catalog No.	Size
TOM34 Polyclonal Concentrated	RC0419-0.1ML	0.1 ml

IHC Procedure*:

Positive Control Tissue: Pancreatic cancer, testis
 Concentrated Dilution: 25-200
 Pretreatment: Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
 Incubation Time and Temp: Overnight at 4°C
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human testis stained with anti-TOM34 using DAB

References:

1. Novel Entropically Driven Conformation-specific Interactions with Tomm34 Protein Modulate Hsp70 Protein Folding and ATPase Activities. Michal Durech, et al. Mol Cell Proteomics. May;15(5):1710-27, 2016.
2. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Mohammed A Aleskandarany, et al. Breast Cancer Res Treat. Nov;136(2):419-27, 2012.